Buy Asmanex

Buy Asmanex has the highest affinity for the GCS receptor Rights:
- 1,5 times higher than that of fluticasone;
- 5 times higher than that of budesonide.

Rapid improvement of the patients – an important indicator of the effectiveness of the drug.

Buy Asmanex exerts a rapid effect, which manifests itself in improving lung function in the first days after initiation of therapy, which improves patient adherence to the treatment.

Efficacy and safety Asmanex studied in double-blind, placebo-controlled studies involving more than two thousand patients with mild to moderate persistent asthma. The studies demonstrated that Asmanex as monotherapy provides control of asthma symptoms and is characterized by high system security.

Buy Asmanex – drugs with high systemic safety.

When using Asmanex having low systemic bioavailability (<1%), most patients the concentration of Mometasone Furoate in blood was below the detection threshold (50 pg / ml). In studies Asmanex showed no systemic effects on the body. In patients with asthma when using the drug in doses ranging from 400 to 1200 mg per day showed no inhibitory effect on the hypothalamic-pituitary-adrenal axis. In the long-term clinical trials Asmanex a dose of 800 mg / day did not reduce the level of cortisol in serum. The above data strongly suggest a high safety of the drug.

Buy Asmanex effective when taking 1 per day.

Patients mild to moderate asthma Asmanex assigned a dose of 400 mg 1 time per day, which greatly improves Compliance. In turn, the correct execution of a doctor’s prescription – a mandatory component in achieving the control signal BA.

Conclusions Asmanex

• IGCC is a priority and the most effective control of drugs in the treatment of asthma.
• About half of all patients with asthma are patients with mild persistent asthma (Article II)..
• ICS monotherapy is recommended for all patients with mild persistent asthma and as a possible choice for patients with asthma of moderate severity.

Asmanex provides the control of asthma symptoms and is effective in the basal monotherapy mild to moderate persistent asthma.

Farm Group Asmanex :

glucocorticosteroid for topical application.

Farm effect Asmanex:

topical corticosteroids, the effect is manifested when applied at doses in which the drug does not cause systemic effects. Long-term treatment does not inhibit the function of the hypothalamic-pituitary-adrenal axis. Anti-inflammatory and antiallergic action. Start a clinically significant effect is noted within the first 12 hours after the first use of the drug.

Pharmacokinetics Asmanex:

The systemic bioavailability of intranasal application – less than 0.1%. Indication: Allergic rhinitis (seasonal or perennial) in adults and children over 12 years. Chronic sinusitis (aggravation, as part of adjuvant therapy).

Contraindications Asmanex:

Hypersensitivity, infectious diseases, nasal mucosa, has recently suffered by surgery or trauma of the nose (until the wound will not heal completely), Children’s age (12 years). With caution. Tuberculosis (active or latent), fungal, bacterial, systemic viral infection, Herpes simplex involving the eye, long-term therapy for systemic effects of corticosteroids, pregnancy, lactation.

Dosage Asmanex

Adults and children over 12 years of preventive and therapeutic dose – 2 inhalations of 50 micrograms in each nostril one time a day, a daily dose – 200 micrograms. If necessary, the dose may be increased to 4 inhalations in each nostril, daily dose – 400 micrograms. After the disappearance of symptoms is recommended lowering the dose. Maintenance dose – 50 micrograms in each nostril, daily dose – 100 micrograms. In the treatment of sinusitis – 2 inhalations (100 mcg) in each nostril 2 times a day. Children from 3 to 12 years – 1 inhalation (50 mcg) in each nostril per day. After an initial “calibration” period during the first 6-7 clicks spray set stereotyped drug delivery, in which each button is released 50 mcg mometasone suspension.

Side effects Asmanex:

Burning, itching, irritation, dryness and atrophy of the mucosa, epistaxis, pharyngitis, candidiasis, bronchospasm, striae, hypertrichosis, secondary infection. Chronic administration of possible systemic side effects. Newborns whose mothers during pregnancy was used corticosteroids, adrenal insufficiency.

Special instructions Asmanex:

Do not use in ophthalmology. During treatment it is necessary to examine the nasal mucosa: a case of bacterial or fungal infection, treatment should be abolished. Before using an inhaler spend 6.7 gauge taps. After a break in treatment for 2 weeks or more before applying to repeat “calibration”. Before use, shake the bottle.